Bevakalp 07
Bevakalp 07
Bevakalp 07
5% 5% 5% 5% 5% 5%
10% 10% 10% 10% 10% 10%
15% 15% 15% 15% 15% 15%
20% 20% 20% 20% 20% 20%
25% 25% 25% 25% 25% 25%
30% 30% 30% 30% 30% 30%
35% 35% 35% 35% 35% 35%
40% 40% 40% 40% 40% 40%
45% 45% 45% 45% 45% 45%
50% 50% 50% 50% 50% 50%
55% 55% 55% 55% 55% 55%
60% 60% 60% 60% 60% 60%
65% 65% 65% 65% 65% 65%
70% 70% 70% 70% 70% 70%
75% 75% 75% 75% 75% 75%
80% 80% 80% 80% 80% 80%
85% 85% 85% 85% 85% 85%
90% 90% 90% 90% 90% 90%
95% 95% 95% 95% 95% 95%
100% 100% 100% 100% 100% 100%
OVARIAN
CANCER
25%
CERVICAL
CANCER
15%
NSCLC
8%
GBM
5%
RCC
5%
In metastatic Colorectal Cancer
Median OS:
25 20.3
20.3
20 15.6
vs
OS (Months)
15 15.6
10
months
(HR=0.66 [95% CI,
05
0.54-0.81], P<0.001)
ABBREVIATION
Improve overall survival in
Metastatic Colorectal Cancer
Median OS:
25
13.0
20
vs
OS (Months)
13.0
15
10.8
10.8
10
months
(HR=0.75 [95% CI,
05
0.63-0.89], P=0.001)
0 Bevacizumab + FOLFOX4 FOLFOX4 alone
(n=286) (n=291)
ABBREVIATION
ABBREVIATION
Improve overall survival in platinum sensitive
recurrent epithelial ovarian Cancer
Median OS:
50
42.6 42.6
40
37.3 vs
OS (Months)
37.3
30
months
20 (HR=0.84 [95% Cl,
0.69-1.01] [IVRS])
10 (HR=0.82 [95%
Cl,0.68-0.996] [eCRF])
0 Bevacizumab + chemotherapy Chemotherapy alone
(n=337) (n=336)
ABBREVIATION
Improve Overall survival in persistent,
recurrent or metastatic Cervical Cancer
Median OS:
25
16.8
20 16.8 VS
OS (Months)
15
12.9
12.9
months
10 (HR=0.74 [95% Cl,
05 0.58-0.94], p=0.0132)
ABBREVIATION